Cytosolic ME1 integrated with mitochondrial IDH2 supports tumor growth and metastasis

Area of Science:

• Biochemistry
• Oncology
• Metabolic pathways

Background:

• Nicotinamide adenine dinucleotide phosphate (NADPH) is crucial for cancer cell redox homeostasis and lipogenesis.
• Targeting NADPH production is a promising cancer therapy strategy, but selective approaches are lacking.
• Understanding differential NADPH pathway exploitation by normal versus cancer cells is unclear.

Purpose of the Study:

• To investigate the differential reliance of cancer cells on NADPH-producing pathways.
• To identify selective therapeutic targets for interfering with NADPH production in cancer.
• To explore the interplay between cytosolic and mitochondrial NADPH production in cancer.

Main Methods:

• Knockdown of ME1 (malic enzyme 1) in cancer cell lines.
• Assessment of intracellular reactive oxygen species (ROS) levels and lipogenesis.
• Analysis of adaptive metabolic reprogramming involving mitochondrial IDH2 (isocitrate dehydrogenase 2), AMPK, and FoxO1.
• Combination therapy involving ME1 ablation and IDH2 inhibition.

Main Results:

• ME1 knockdown selectively impairs cancer cell proliferation and increases anoikis by raising ROS and reducing lipogenesis.
• Cancer cells adapt to ME1 interference via AMPK-FoxO1-mediated upregulation of mitochondrial IDH2 to restore NADPH and mitigate ROS.
• Combined ME1 ablation and IDH2 inhibition effectively depletes NADPH, overcomes resistance, and induces apoptosis.
• Disrupting the integrated cytosolic ME1 and mitochondrial IDH2 axis impedes tumor growth and metastasis.

Conclusions:

• Cytosolic ME1 and mitochondrial IDH2 form an integrated metabolic axis essential for tumor growth and metastasis.
• Targeting metabolic compensation by blocking mitochondrial-cytosolic NADPH transport offers a selective strategy against NADPH-dependent cancers.
• This approach holds promise for treating cancers reliant on NADPH-driven antioxidant systems.